A Houston company has joined a new Amazon program focused on Latin American founders. Photo courtesy of Amazon

Amazon named the 20 startups joining its accelerator that will connect Latinx founders to its network of mentors, provide programming, and even dole out funding.

The AWS Impact Accelerator Latino Founders Cohort is a part of Amazon's $30 million commitment to supporting underrepresented startup founders. The eight-week program started this week in Amazon's Seattle headquarters.

“This cohort of the AWS Impact Accelerator aims to highlight the viability and ingenuity of Latino-led startups, so the VC community can increase support to these founders,” says Howard Wright, vice president and global head of startups at AWS, in the news release. “We’re looking forward to playing an active role in helping these companies turbocharge their growth through access to capital, experts, and all of the innovations that the AWS tech stack has to offer.”

Houston-based Ease, founded by Mario Amaro in 2018, the health care fintech platform allows for medical professionals to start, grow, and manage their private practices with bookkeeping tools and other software infrastructure. So far, the company has worked with more than 300 practices. Per Cruncbase data, the company has raised $2.8 million in pre-seed and grant funding. According to Amazon, the company's investors include Slauson & Co. and Precursor Ventures.

Mario Amaro, founder of Ease, was selected for one of Amazon's accelerator programs. Photo courtesy of Amazon

Last year, Ease was named among the 50 companies in the inaugural cohort of the Google for Startups Latino Founders Fund. In that program, each company received an equity-free $100,000 investment, as well as programming and support from Google, mentorship from technical and business experts, access to free mental health therapy, and more.

Ease stood out among the nearly 1,100 submissions to the program, according to the release, and joins 19 other companies from across the country and even Argentina, Brazil, Colombia, Mexico, Venezuela, and Puerto Rico. Each of the cohort companies will receive up to $225,000 in cash and AWS Activate credits, alongside a training curriculum, networking opportunities with Amazon staff and potential investors, and ongoing advisory support.

The other startups in the program include:

  • Alvva, a, immigrant-focused fintech platform from California
  • Cogniflow, a personal AI platform founded in Colombia with a New York US HQ
  • Deskfy, a marketing portal from Brazil with its US HQ in Delaware
  • DivySci Software, an edtech organization founded in New York
  • EducUp, an edtech company from Florida
  • Fielder, a Mexico-founded enterprise software-as-a-service with US-based operations in Delaware
  • GamerSafer, a security tech company within gaming from California
  • Kigüi, a Mexican money-saving grocery app
  • Kuentro, a Venezuelan affordable hiring platform that caters to middle- and working-class job seekers
  • Lazo Fintech Inc, a Florida-based fintech and legal platform
  • Leantime, a developer tool from North Carolina
  • Monadd, a Florida-founded personal finance platform
  • PilotoMail, a remote work platform founded in Puerto Rico
  • Sign-Speak, a New York startup with an American Sign Language device
  • STIGMA, a mental health mobile app from Illinois
  • Outtrip, a Argentina-founded tourism platform with US operations in Delaware
  • Panda Salud, a Mexico-based platform connecting health care small businesses with diagnostic test providers
  • Tienditapp, a Mexico-based app with a last-mile delivery model
  • TuCuota, a payment collections tool from Argentina
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.